Teva loss narrows as revenue grows
With the recovery of the generic drug market in the United States Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa) It ended the first quarter of 2024 with revenues of $3.81 billion, an…